Clinical Trial Update: A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab in myelodysplastic syndromes with excess marrow blasts has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED